PMID- 12073179
OWN - NLM
STAT- MEDLINE
DCOM- 20030108
LR  - 20181130
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 28 Suppl 2
DP  - 2002 Jun
TI  - Treatment of symptomatic venous thromboembolism: improving outcomes.
PG  - 41-8
AB  - Antithrombotic therapy with unfractionated heparin (UFH) and warfarin for the 
      treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) became 
      widely accepted in the early 1960s. Subsequent clinical trials have focused on 
      the importance of early intravenous UFH in the treatment of venous thromboembolic 
      events, the method of heparin administration, the importance of rapid 
      anticoagulation to prevent recurrent venous thromboembolism (VTE), and the 
      optimal duration of UFH administration. Low-molecular-weight heparin (LMWH) 
      represents a significant advance over UFH therapy for VTE. Developed in the late 
      1980s, LMWH has become an excellent alternative to UFH because it offers superior 
      efficacy and safety, improved pharmacokinetics, longer half-life, and once- or 
      twice-daily subcutaneous administration without the need for laboratory 
      monitoring. Fondaparinux is the first of a new class of antithrombotic agents 
      that targets factor Xa. Based on studies of the heparin binding site of 
      antithrombin, this novel pentasaccharide has superior pharmacokinetics and 
      bioavailability when compared with LMWH and can be administered once daily. 
      Studies in patients undergoing major orthopedic surgery and in those with 
      proximal DVT indicate that the efficacy and safety of fondaparinux may represent 
      an improvement over those of LMWH.
FAU - Buller, Harry R
AU  - Buller HR
AD  - Department of Vascular Medicine, Academic Medical Center at the University of 
      Amsterdam, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Polysaccharides)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Double-Blind Method
MH  - Fondaparinux
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Polysaccharides/administration & dosage/*therapeutic use
MH  - Pulmonary Embolism/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Thromboembolism/*drug therapy
MH  - Treatment Outcome
RF  - 48
EDAT- 2002/06/20 10:00
MHDA- 2003/01/09 04:00
CRDT- 2002/06/20 10:00
PHST- 2002/06/20 10:00 [pubmed]
PHST- 2003/01/09 04:00 [medline]
PHST- 2002/06/20 10:00 [entrez]
AID - 10.1055/s-2002-32315 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2002 Jun;28 Suppl 2:41-8. doi: 10.1055/s-2002-32315.